UK Mid Cap and UK Opps funds affected
Too early to crystallise losses
Outperformers to look out for
More high-quality companies raising capital
Singapore wealth fund to take minority stake
Originally held the trust in 2015
When it comes to finding growth in the UK, we are positive on the pharmaceuticals sector.
Amid a tough period for fund performance
Describes Prothena disappointment
From top holding to 1% in 12 months
Key to maintaining a balanced approach
Hurt by raft of share price falls
Reduced holding gradually over time
Firms seen double-digit falls
Largest daily share price fall
Previously warned on pharma dividends
AstraZeneca is top holding at 7.4%
What is worse: running a distribution warehouse in a sleepy part of the UK which is described as a Victorian workhouse, or bribing people to sell your products in two of the most important countries in the world?
Concerns over sector M&A
Mark Barnett has told Investment Week he is "concerned" over the fortunes of GlaxoSmithKline, a core holding in the Invesco Perpetual Income funds which he began running at the start of March 2014.
Threadneedle's Richard Colwell is adding more to stocks including Centrica and GlaxoSmithKline as he seeks contrarian equity income plays for the months ahead.
Neptune Investment Management's Mark Martin has overhauled the £66m UK Opportunities fund since taking over as lead manager, turning it into a higher conviction portfolio with fewer positions.
Embattled supermarket Tesco has suffered a further blow in the form of an investigation by the industry regulator into its treatment of suppliers.
Managing the low inflation challenge